BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Reports

10 APAC Biomanufacturing Plants Scheduled to Come Online Before End-2027, and How Many Have Already Slipped

Every capacity plan written in an Asian biopharma company this quarter rests on a calendar it did not write. Somewhere in the spreadsheet is an assumption ...

November 10, 2026 | News

KaliVir’s VET3-TGI Regimens Show 71% Response Rate in Advanced Skin Cancers in Early Trial

Preliminary data from intratumoral VET3-TGI presented in oral session at SITC 2026; abstract recognized among SITC’s top 150 abstracts Responses o...

November 10, 2026 | News

OncoC4 Reports 33% Response Rate for Cesalatamig in Lung Cancer Resistant to PD-(L)1 Therapy

33% investigator-assessed objective response rate and 90% disease control rate at 10 mg/kg every three weeks in patients with PD-(L)1-resistant/refrac...

November 09, 2026 | News

APAC Antibody-Drug Conjugates Past Phase 2, and Who Owns Them Now

Seventeen of them have already been licensed outside their home market, and the companies that will sell most of them in the US and Europe are Merck, Astra...

November 05, 2026 | Analysis

China's 2026 Reimbursement Lists: 10 Drugs That Will Show Where Beijing Is Paying, and the Commercial List's Second Year

Where things stand. As of 2 November 2026, the National Healthcare Security Administration (NHSA) has not published the 2026 National Reimbursement Drug Li...

November 03, 2026 | Regulatory

InventisBio’s Nomelcitinib Achieves Both Primary and Key Secondary Endpoints in Phase III Psoriasis Trial

InventisBio Co., Ltd. announced that its JH2 selective TYK2 inhibitor nomelcitinib (D-2570) has met both the primary endpoint and the key seconda...

November 03, 2026 | News

Nuance Pharma Doses First Patient in China Phase III Trial of Actair for House Dust Mite Allergy

Nuance Pharma announced that the first patient has been dosed in the REACH Phase III clinical trial evaluating STG320 (Actair®) for the treatment of ho...

November 03, 2026 | News

Japan's FY2027 Off-Year Drug Price Revision: 8 Numbers That Decide Who Pays

Japan's off-year drug price revision stopped being a question of whether some time ago. When the health and finance ministers closed the FY2026 budget roun...

October 29, 2026 | Analysis

Akeso and Summit Advance Ivonescimab into Seventh Global Registrational Trial Targeting Biliary Tract Cancer

Akeso, Inc. announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its global partner for ivonescimab, has entered into a clinical trial collaboration wit...

October 23, 2026 | News

What Eight APAC Regulators Have Actually Published on AI in Drug Development

Ask a regulatory affairs lead in Tokyo, Seoul or Singapore what the rules are for using a machine learning model in a drug submission, and the honest answe...

October 22, 2026 | Analysis

FDA Warning Letters to APAC Drug Facilities in Fiscal 2026: The Full Ledger, Normalised

Every October, the same headline writes itself. India leads the count of US FDA warning letters to Asian drug plants, China follows, and the rest of the re...

October 21, 2026 | Analysis

How Long It Takes to Start a Clinical Trial in 8 APAC Markets, Timed

If you are building a 2027 trial budget this month, you are probably working from a spreadsheet with one row per country and a column headed "start-up". Mo...

October 19, 2026 | News

Semaglutide Generics, Six Months In: Every Launch in India, Every Price, and Where China Stands

AT A GLANCE 12 generic makers with a public launch in India, selling 20 brands between them Rs 1,290 lowest stated monthly price, for vials...

October 09, 2026 | Analysis

Every CAR-T Therapy Approved in Asia-Pacific, and What It Costs

Method in brief What counts. A CAR-T cell therapy approved on one of seven national registers: China's NMPA, Japan's PMDA and MHLW, Korea's MFDS, ...

October 08, 2026 | Analysis

Stay Connected